Avacta To Evaluate Affimers As Checkpoint Inhibitors, Anticoagulants
This article was originally published in The Pink Sheet Daily
Executive Summary
After raising $34 million from Britain’s stock market, the U.K. biotech now plans to develop its Affimer proteins as therapeutics as well as research reagents, to enable two complementary strands of business.